Biomarkers for Prostate Cancer: From Diagnosis to Treatment

作者：Jiayan Chen, Peiyan Wang, Mingzhu Liu, Feng Lyu, Mingwei Ma, Xueying Ren, Xianshu Gao · 发表于：Diagnostics · 年份：2023 · DOI：10.3390/diagnostics13213350 · 被引用次数：65 · 研究领域：Prostate Cancer Treatment and Research、Cancer, Lipids, and Metabolism、Tannin, Tannase and Anticancer Activities

Prostate cancer (PCa) is a widespread malignancy with global significance, which substantially affects cancer-related mortality. Its spectrum varies widely, from slow-progressing cases to aggressive or even lethal forms. Effective patient stratification into risk groups is crucial to therapeutic decisions and clinical trials. This review examines a wide range of diagnostic and prognostic biomarkers, several of which are integrated into clinical guidelines, such as the PHI, the 4K score, PCA3, Decipher, and Prolaris. It also explores the emergence of novel biomarkers supported by robust preclinical evidence, including urinary miRNAs and isoprostanes. Genetic alterations frequently identified in PCa, including BRCA1/BRCA2, ETS gene fusions, and AR changes, are also discussed, offering insights into risk assessment and precision treatment strategies. By evaluating the latest developments and applications of PCa biomarkers, this review contributes to an enhanced understanding of their role in disease management.